A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer

Clinical trial NCT02025192 · COMPLETED

Trial details

NCT number: NCT02025192
Sponsor: Seagen Inc.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

HER2 Positive Metastatic Breast Cancers

Start date: 2013-12-31
Primary completion: 2017-10-03
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.